Not good news on the clinically available monoclonals vs newer covid lineages.

"Our data reveal that emerging omicron sublineages are resistant to most (ie, BA.4.6, BA.2.75.2, and BJ.1) or all (BQ.1.1) clinically used mAbs. As a consequence, in patients at high risk, treatment with mAbs alone might not provide a therapeutic benefit in regions of the globe in which BQ.1.1 is spreading, suggesting that additional treatment options (eg, paxlovid or molnupiravir) should be considered. Furthermore, novel, broadly active mAbs are urgently needed for prophylactic or therapeutic treatment, or both, in patients at high risk."

#COVID #Antibody #MonoclonalAntibody

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00733-2/fulltext